B. Braun Medical, Inc.; Withdrawal of Approval of Abbreviated New Drug Application of Hydroxyethyl Starch, 52685 [2021-20511]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 181 / Wednesday, September 22, 2021 / Notices
4027, Attn: August 30, 2021 ACIP
Meeting.
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received in conformance with the
https://www.regulations.gov suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
In accordance with 41 CFR 102–
3.150(b), less than 15 calendar days’
notice is being given for this meeting
due to the exceptional circumstances of
the COVID–19 pandemic and rapidly
evolving COVID–19 vaccine
development and regulatory processes.
The Secretary of Health and Human
Services has determined that COVID–19
is a Public Health Emergency.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, ACIP Committee
Management Specialist, Centers for
Disease Control and Prevention,
National Center for Immunization and
Respiratory Diseases, 1600 Clifton Road
NE, MS–H24–8, Atlanta, GA 30329–
4027; Telephone: 404–639–8367; Email:
ACIP@cdc.gov.
comments must be received on or before
August 30, 2021.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–20478 Filed 9–21–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–N–0921]
B. Braun Medical, Inc.; Withdrawal of
Approval of Abbreviated New Drug
Application of Hydroxyethyl Starch
AGENCY:
Food and Drug Administration,
HHS.
Notice.
Public Participation
ACTION:
Written Public Comment: The docket
will close on August 30, 2021. Written
SUMMARY:
The Food and Drug
Administration (FDA or Agency) is
Application No.
ANDA BA 110013/0032 .....
withdrawing approval of abbreviated
new drug application (ANDA)
BA110013/0032 for 6 Percent
Hydroxyethyl Starch 130/0.4 in 0.9
Percent Sodium Chloride Injection in
EXCEL® Plastic Container, held by B.
Braun Medical, Inc. B. Braun Medical,
Inc., requested in writing that the
Agency’s approval of the application be
withdrawn because the drug is no
longer being marketed and has waived
its opportunity for a hearing.
Approval is withdrawn as of
October 22, 2021.
DATES:
FOR FURTHER INFORMATION CONTACT:
Myrna Hanna, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 7301,
Silver Spring, MD 20993–0002, 240
402–7911.
B. Braun
Medical Inc., 901 Marcon Blvd.,
Allentown, PA 18109, has requested
that FDA withdraw approval of ANDA
BA110013/0032, pursuant to
§ 314.150(c) (21 CFR 314.150(c)),
because the drug is no longer being
marketed. By its request, B. Braun
Medical Inc. has also waived its
opportunity for a hearing. Withdrawal
of approval of an application under
§ 314.150(c) is without prejudice to
refiling.
SUPPLEMENTARY INFORMATION:
Proprietary name
6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride Injection in EXCEL® Plastic Container.
Therefore, approval of the application
listed in the table, and all amendments
and supplements thereto, is hereby
withdrawn as of October 22, 2021.
Introduction or delivery for introduction
into interstate commerce for products
without an approved new drug
application or ANDA violates section
301(a) and (d) of the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. 331(a) and
(d)). The drug product that is listed in
the table above that is in inventory on
October 22, 2021 may continue to be
dispensed until the inventory has been
depleted or the drug product has
reached its expiration date or otherwise
becomes violative, whichever occurs
first.
Dated: September 16, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for
Policy.
[FR Doc. 2021–20511 Filed 9–21–21; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
52685
16:44 Sep 21, 2021
Jkt 253001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–N–3326]
Reauthorization of the Biosimilar User
Fee Act; Public Meeting; Request for
Comments
AGENCY:
Food and Drug Administration,
HHS.
Notice of public meeting;
request for comments.
ACTION:
The Food and Drug
Administration (FDA or Agency) is
hosting a virtual public meeting to
discuss proposed recommendations for
the reauthorization of the Biosimilar
User Fee Act (BsUFA) for fiscal years
(FYs) 2023 through 2027. The BsUFA
authorizes FDA to collect user fees to
support the process for the review of
biosimilar biological product
applications. The current legislative
SUMMARY:
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
authority for BsUFA expires in
September 2022. At that time, new
legislation will be required for FDA to
continue collecting user fees in future
fiscal years. Following discussions with
the regulated industry and consultations
with public stakeholders, the Federal
Food, Drug, and Cosmetic Act (FD&C
Act) directs FDA to publish the
recommendations for the reauthorized
program in the Federal Register, hold a
meeting at which the public may
present its views on such
recommendations, and provide for a
period of 30 days for the public to
provide written comments on such
recommendations. FDA will then
consider such public views and
comments and revise such
recommendations, as necessary.
The public meeting will be held
on November 2, 2021, from 9 a.m. to 12
p.m. Eastern Time, and will be held by
webcast only. Submit either electronic
or written comments on this public
DATES:
E:\FR\FM\22SEN1.SGM
22SEN1
]]>Agencies
[Federal Register Volume 86, Number 181 (Wednesday, September 22, 2021)]
[Notices]
[Page 52685]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-20511]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2021-N-0921]
B. Braun Medical, Inc.; Withdrawal of Approval of Abbreviated New
Drug Application of Hydroxyethyl Starch
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is
withdrawing approval of abbreviated new drug application (ANDA)
BA110013/0032 for 6 Percent Hydroxyethyl Starch 130/0.4 in 0.9 Percent
Sodium Chloride Injection in EXCEL[supreg] Plastic Container, held by
B. Braun Medical, Inc. B. Braun Medical, Inc., requested in writing
that the Agency's approval of the application be withdrawn because the
drug is no longer being marketed and has waived its opportunity for a
hearing.
DATES: Approval is withdrawn as of October 22, 2021.
FOR FURTHER INFORMATION CONTACT: Myrna Hanna, Center for Biologics
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240
402-7911.
SUPPLEMENTARY INFORMATION: B. Braun Medical Inc., 901 Marcon Blvd.,
Allentown, PA 18109, has requested that FDA withdraw approval of ANDA
BA110013/0032, pursuant to Sec. 314.150(c) (21 CFR 314.150(c)),
because the drug is no longer being marketed. By its request, B. Braun
Medical Inc. has also waived its opportunity for a hearing. Withdrawal
of approval of an application under Sec. 314.150(c) is without
prejudice to refiling.
------------------------------------------------------------------------
Application No. Proprietary name
------------------------------------------------------------------------
ANDA BA 110013/0032....................... 6% Hydroxyethyl Starch 130/
0.4 in 0.9% Sodium Chloride
Injection in EXCEL[supreg]
Plastic Container.
------------------------------------------------------------------------
Therefore, approval of the application listed in the table, and all
amendments and supplements thereto, is hereby withdrawn as of October
22, 2021. Introduction or delivery for introduction into interstate
commerce for products without an approved new drug application or ANDA
violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. 331(a) and (d)). The drug product that is listed in the
table above that is in inventory on October 22, 2021 may continue to be
dispensed until the inventory has been depleted or the drug product has
reached its expiration date or otherwise becomes violative, whichever
occurs first.
Dated: September 16, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2021-20511 Filed 9-21-21; 8:45 am]
BILLING CODE 4164-01-P
